Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06194448 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
A Phase 2 study of Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT06194448: Active Phase 2 study of Lung Cancer, sponsored by AstraZeneca.
NCT06194448 is a Phase 2 study of Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 76 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06194448, a Phase 2 study of Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Primary Outcome
PFS is defined as the time from date of first dose until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Cisplatin or Carboplatin; Pemetrexed or Paclitaxel
- DRUG Radiation
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Changsha
- Research Site - Guangzhou
- Research Site - Hangzhou
- Research Site - Harbin
- Research Site - Hefei
- Research Site - Jinan
- Research Site - Nanning
- Research Site - Shanghai
- Research Site - Tianjin
- Research Site - Wuhan
- Research Site - Wuhan
- Research Site - Zhengzhou
- Research Site - Haifa
- Research Site - Jerusalem
- Research Site - Tel Aviv
- Research Site - Cheongju-si
- Research Site - Seongnam-si
California
- Research Site - La Jolla
- Research Site - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-04-21 |
| Est. Completion | 2027-07-07 |
| Phase | Phase 2 |
What the registry record for NCT06194448 still lists
NCT06194448 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.
NCT06194448 names 20 study sites across 2 states, led by Other, California.
Frequently Asked Questions
What is clinical trial NCT06194448 about?
NCT06194448 is a clinical study titled "To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations". The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
What is the current status of trial NCT06194448?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2024-04-21. Estimated completion is 2027-07-07.
What conditions does trial NCT06194448 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT06194448?
The interventions under investigation include: Osimertinib (DRUG), Cisplatin or Carboplatin; Pemetrexed or Paclitaxel (DRUG), Radiation (DRUG).
Who is sponsoring clinical trial NCT06194448?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06194448 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06194448's enrollment target sits among peer trials
76 214th of 409 higher than 196 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI